As of last week, Vanderbilt has updated the process used to facilitate patient participation in BioVU, the Medical Center’s DNA repository.

Vanderbilt’s biobank, BioVU, has begun to collect and store plasma, the liquid part of blood, to aid studies of diseases ranging from heart failure and hypertension to breast cancer.

A person’s mitochondrial gene “signature” could predict risk for diabetic retinopathy and guide early intervention strategies.

Vanderbilt University has formed a scientific partnership with Celgene Corporation to investigate new uses for the company’s anti-inflammatory drugs that are already on the market.

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH).

Electronic medical records linked to DNA biobanks are a valid resource for defining and understanding the genetic factors that contribute to drug response.

Vanderbilt researchers have discovered that variation in the gene encoding the potassium channel GIRK1 plays a role in modulating human pain perception.